Abercrombie & Fitch Co. Q4 Profit Misses Estimates

Abercrombie & Fitch Co. (ANF) reported fourth quarter net income attributable to A&F of $38.33 million compared to $65.51 million, prior year. Net income per share was $0.75 compared to $1.12.

Net income per share was $0.81 on an adjusted non-GAAP basis, compared to $1.14. On average, seven analysts polled by Thomson Reuters expected the company to report profit per share of $0.86, for the quarter. Analysts' estimates typically exclude special items.

Gross profit rate for the fourth quarter declined 260 basis points as compared to last year to 55.7%, driven by the adverse impact of exchange rates and higher product costs with higher cotton costs and inventory reserves more than offsetting lower freight costs.

Net sales were $1.2 billion, up 3% as compared to last year on a reported basis and 5% on a constant currency basis. The growth in sales was led by 14% growth in Abercrombie brands. Analysts on average had estimated $1.18 billion in revenue.

For fiscal 2023, the company expects net sales growth in the range of 1 to 3%. For the first quarter of fiscal 2023, the company expects net sales to be around flat to fiscal first quarter 2022 level of $813 million.

"As we look to 2023, we remain cautiously optimistic on consumer demand," said Fran Horowitz, CEO.

Shares of Abercrombie & Fitch Co. are down 3% in pre-market trade on Wednesday.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Elon Musk's brain implant firm Neuralink said it has received approval from the U.S. Food and Drug Administration to conduct first-in-human clinical trials. In a tweet, Neuralink said, "We are excited to share that we have received the FDA's approval to launch our first-in-human clinical study! T.W. Garner Food Co. is recalling 50,688 bottles of 12 oz. Texas Pete Buffalo Wing Sauce citing undeclared soy, the U.S. Food and Drug Administration said. The agency noted that some of the bottles may contain Texas Pete Extra Mild Wing Sauce which contains soy. The recall involves Texas Pete Buffalo Wing Sauce with best used by 120623T 065239 UPC 0 75500 10011 6. The U.S. Food and Drug Administration approved Pfizer Inc's COVID-19 oral antiviral pill Paxlovid for the treatment of mild-to-moderate COVID-19 in adults. Paxlovid is the first oral treatment, and the fourth drug, approved by the agency to treat COVID-19 in adults. Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) has been approved to treat adults who are at high...
Follow RTT